Artelo Biosciences, Inc. (ARTL)
5.85
-0.13
(-2.17%)
USD |
NASDAQ |
Sep 10, 15:22
Artelo Biosciences EPS Diluted (Quarterly) : -0.8949 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.8949 |
| March 31, 2026 | -4.003 |
| December 31, 2025 | -6.191 |
| September 30, 2025 | -11.89 |
| June 30, 2025 | -16.83 |
| March 31, 2025 | -13.01 |
| December 31, 2024 | -20.99 |
| September 30, 2024 | -6.312 |
| June 30, 2024 | -13.57 |
| March 31, 2024 | -13.98 |
| December 31, 2023 | -17.35 |
| September 30, 2023 | -14.95 |
| June 30, 2023 | -10.08 |
| March 31, 2023 | -13.66 |
| December 31, 2022 | -21.05 |
| September 30, 2022 | -14.72 |
| June 30, 2022 | -15.57 |
| March 31, 2022 | -12.54 |
| August 31, 2021 | -20.77 |
| May 31, 2021 | -26.28 |
| February 28, 2021 | -29.66 |
| November 30, 2020 | -37.91 |
| August 31, 2020 | -55.56 |
| May 31, 2020 | -74.09 |
| February 29, 2020 | -107.98 |
| Date | Value |
|---|---|
| November 30, 2019 | -104.92 |
| August 31, 2019 | -81.28 |
| May 31, 2019 | -361.82 |
| February 28, 2019 | -59.81 |
| November 30, 2018 | -85.71 |
| August 31, 2018 | -106.47 |
| May 31, 2018 | -97.96 |
| February 28, 2018 | -116.23 |
| November 30, 2017 | -52.75 |
| August 31, 2017 | -22.08 |
| May 31, 2017 | -23.70 |
| February 28, 2017 | -3.672 |
| November 30, 2016 | -2.70 |
| August 31, 2016 | 0.00 |
| May 31, 2016 | 0.00 |
| February 29, 2016 | 0.00 |
| November 30, 2015 | 0.00 |
| August 31, 2015 | 0.00 |
| May 31, 2015 | 0.00 |
| February 28, 2015 | 0.00 |
| November 30, 2014 | 0.00 |
| August 31, 2014 | 0.00 |
| May 31, 2014 | 0.00 |
| February 28, 2014 | 0.00 |
| November 30, 2013 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.427M |
| Total Expenses (Quarterly) | 2.427M |
| Enterprise Value | 20.90M |
| Earnings Yield | -392.9% |
| Normalized Earnings Yield | -371.07 |